IMP24011. Phase III, randomised, double blind, placebo-controlled, multicentre study evaluating 12 weeks subcutaneous therapy with Genentech efalizumab in patients with moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis [industry submission]. Feltham: Serono Ltd; 2004.

Authors
Category Primary study
Year Not known
This article has no abstract
Epistemonikos ID: 65c561a6f2a943ea61c74e8af7ec6a262d7b1281
First added on: Apr 25, 2017